SK Biopharmaceuticals, Buy Opinion Maintained Despite Target Price Cut… What's the Future of Xcopri?
DS Investment & Securities lowered SK Biopharmaceuticals' target price from KRW 160,000 to KRW 145,000, but maintained a 'Buy' rating. This decision comes despite strong Q1 earnings that significantly exceeded market expectations, reflecting a more conservative outlook on future uncertainties that could impact corporate value.
Key takeaway
"SK Biopharmaceuticals, Buy Opinion Maintained Despite Target Price Cut… What's the Future of Xcopri?" — BullBear's AI rates this story as a mixed, direction-neutral signal, with a market-impact score of 35 out of 100. DS Investment & Securities lowered SK Biopharmaceuticals' target price from KRW 160,000 to KRW 145,000, but maintained a 'Buy' rating. This decision comes despite strong Q1 earnings that significantly exceeded market expectations, reflecting a more conservative outlook on future uncertainties that could impact corporate value. Reported by TokenPost on May 26, 2026. The call is verified against the actual 24-hour price move on BullBear's public conviction ledger.
Get the next high-impact catalyst
Telegram alerts when our AI scores a story 80+/100 impact (~1-3 per day, no spam). Verified 30d hit rate 53.3%.